Rapid advances in neurological treatments
Advances in the neurosciences have placed the field in the position where it is poised to significantly reduce the burden of nervous system disorders. However, drug discovery, development and translation for nervous system disorders still pose many unique challenges. KCAS Bio is here to help you meet the challenges of your neurological drug development project.
Neurological treatment research, by leading scientists
When clients come to KCAS Bio in need of development services they will often ask what matrices with which we have experience. Questions we are asked included “Do you have experience developing methods in difficult matrices?” “Do you have experience developing methods for the more complicated and unstable chemical modalities?” “Can you develop a high sensitivity assay?” At KCAS Bio, methods are developed with a fit-for-purpose design in mind, based on our Client’s needs. This can range from developing an assay in support of a proof-of-concept to a GLP-compliant investigation. We rely on highly sensitive technologies like the Simoa® or Lumipulse® technologies that allow for the detection, in the blood, of brain-related biomarkers present at very low concentrations and indicative of disease progression, relapse or therapeutic efficacy in neurological disorders such as Multiple sclerosis (MS) or Alzheimer’s Disease (AD).
We employ rigorous quality practices that go beyond our competition. Processes are continuously improved to ensure we consistently deliver a complete outsourcing experience to clients.
KCAS Bio provides high quality science and data services that have benefits for the entire drug development journey.
Agile, responsive, and easy to work with
We prepare and adapt our neurological research based on a deep understanding of your drug development ambitions and wider business objectives.
Neurodegenerative diseases affect millions worldwide. Fifty million people are living with Alzheimer’s disease or other dementias. Although Alzheimer’s disease is one of the most recognized, it is just one of many neurological disorders, such as Multiple Sclerosis, Parkinson’s, or Huntington’s disease. These conditions lead to a…
Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or biologics and Anti-Drug Antibodies (ADA). Throughout the…
Tell us how we can help with your project
We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.